Cytori Therapeutics
(NSDQ:CYTX) said yesterday that it completed its acquisition of San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs.
In late January, San Diego-based Cytori said it planned to buy Azaya in a stock deal, offering Azaya shareholders $2 million in CTYX stock.
Cytori also said that it paid $2 million upfront for costs associated with Azaya’s new manufacturing facility in San Antonio.
Get the full story at our sister site, Drug Delivery Business News.
The post Cytori launches nanoparticle program after acquiring Azaya Therapeutics appeared first on MassDevice.